Mormodica charantia polypeptide multi-target gene regulation
Solution Overview
Problem
Current target therapy drugs are limited in their ability to address multiple diseases simultaneously, often focusing on single targets or diseases, which increases the cost and complexity of drug discovery and development.
Innovation Solution
A polypeptide with an amino acid sequence of SEQ ID No. 1 or a homologous sequence with more than 90% identity is used in a medicament to regulate multiple organs and multiple genes, targeting inflammatory transcription factors like PPAR-γ, NF-κB, and Sirt1 to treat conditions such as inflammation, metabolic syndrome, and obesity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If current target therapy drugs focus on single targets or diseases, then the drug development process becomes simpler and cheaper, but the ability to address multiple diseases simultaneously is limited
Solution Approach 1:
The patent applies universality by designing a pharmaceutical composition that can simultaneously target multiple diseases and multiple molecular targets. The composition includes compounds that can modulate various transcription factors and signaling pathways, enabling one drug to treat multiple conditions such as inflammatory diseases, metabolic disorders, and cancer, thereby resolving the contradiction between versatility and complexity
Solution Approach 2:
The patent merges multiple therapeutic functions into a single pharmaceutical composition. By combining compounds that target different molecular pathways (e.g., PPAR-γ, NF-κB, Sirt1) in one formulation, the invention achieves multi-disease treatment capability while streamlining the drug development process, as the composition can be developed and tested as a unified product rather than multiple separate drugs
2Reliability
If current target therapy drugs focus on single targets, then the drug development cost is lower, but the therapeutic outcome for complex diseases is limited
Solution Approach 1:
The pharmaceutical composition is designed with multi-functionality to reliably treat complex diseases by simultaneously modulating multiple transcription factors and signaling pathways. The composition includes compounds that can affect PPAR-γ, NF-κB, Sirt1, and other targets, providing comprehensive therapeutic coverage for complex conditions like metabolic syndrome and inflammatory diseases, thereby improving therapeutic outcomes beyond what single-target drugs can achieve
3Reliability
If a polypeptide targets multiple genes and multiple targets, then the therapeutic benefits for various diseases are improved, but the mechanism of action becomes more complex
Solution Approach 1:
The patent applies segmentation by dividing the complex mechanism of action into distinct functional modules. The pharmaceutical composition targets specific transcription factors (PPAR-γ, NF-κB, Sirt1) and signaling pathways separately, allowing each component's effect to be understood and optimized independently. This modular approach enables comprehensive therapeutic benefits while making the overall mechanism more comprehensible and manageable
Data Source
Figure 1
Figure 2
Figure 3
AI summary
This invention discloses methods for regulating multiple organs, multiple genes and multiple targets by using a polypeptide, wherein the polypeptide comprising the amino acid sequence of SEQ ID No.1 and/or homology thereof. The present polypeptide reveals the potency to regulate transcription of multiple genes and expression of multiple targets. Therefore, a composition having the polypeptide can be applied to regulate the expression of multiple targets in multiple organs of patients. Furthermore, the composition having the polypeptide can be applied in therapies of inflammation and inflammatory disorders, suppression of fatty liver disease progression, suppression of the diseases caused by fatty accumulation, prevention and therapy of muscular atrophy, and avoiding the complications of diabetes.